The takeaway
In this diabetes trial, the two higher liraglutide doses and glimepiride lowered blood sugar by about one percentage point, while their weight changes differed. The 0.6 mg liraglutide and placebo groups did not have the same blood-sugar result.
What researchers compared
After a metformin run-in, the 26-week double-blind, double-dummy trial randomized 1,091 adults with type 2 diabetes; 1,087 received treatment. Everyone continued metformin. HbA1c was the primary outcome; weight was secondary. The liraglutide doses were diabetes doses, not the 3 mg regimen later studied for weight management.
The weight results
The chart shows changes from each group’s starting weight, not differences versus placebo. Efficacy analysis required treatment exposure and a postbaseline measurement for the relevant outcome; researchers used last-observation-carried-forward imputation for missing measurements. The two higher liraglutide doses and glimepiride had similar blood-sugar reductions, but this does not establish overall equivalence or a universally best medicine.
All groups also received metformin; within-group changes
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Liraglutide 0.6 mg | −1.8 kg |
| Liraglutide 1.2 mg | −2.6 kg |
| Liraglutide 1.8 mg | −2.8 kg |
| Glimepiride | +1.0 kg |
| Placebo | −1.5 kg |
The trade-offs
Minor low-blood-sugar episodes affected about 3% of liraglutide or placebo participants versus 17% receiving glimepiride. No major episodes were observed, which does not establish zero future risk. Gastrointestinal events affected 35%–44% across liraglutide groups versus 17% in each control group. Thirty-six liraglutide participants withdrew because of nausea, vomiting or diarrhea. One participant in the 1.2 mg liraglutide group and one receiving glimepiride had acute pancreatitis.
Why the methods matter
Completion ranged from about 79%–86% across liraglutide groups, versus 86% with glimepiride and 61% with placebo. These are not all adverse-event withdrawals, and carried-forward estimates are not the same as observing everyone at week 26. Two authors were affiliated with Novo Nordisk; the paper acknowledged company writing assistance and financial disclosures.